Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aspirin resistance - does it clinically matter?

Karsten Schrör1, T Hohlfeld, A-A Weber

  • 1Institut für Pharmakologie und Klinische Pharmakologie, Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität, Universitätsstr. 1, Geb. 22.21, 40225, Düsseldorf, Germany. kschroer@uni-duesseldorf.de

Clinical Research in Cardiology : Official Journal of the German Cardiac Society
|August 11, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Icosapent ethyl reduces arterial thrombosis by inhibition of cyclooxygenase-1-induced platelet reactivity.

Science translational medicine·2025
Same author

Drug-Drug Interaction between Antiplatelet Therapy and Lipid-Lowering Agents (Statins and PCSK9 Inhibitors).

Thrombosis and haemostasis·2022
Same author

Platelet-Mediated Transfer of Cardioprotection by Remote Ischemic Conditioning and Its Abrogation by Aspirin But Not by Ticagrelor.

Cardiovascular drugs and therapy·2022
Same author

Aspirin as an Adjunctive Pharmacologic Therapy Option for COVID-19: Anti-Inflammatory, Antithrombotic, and Antiviral Effects All in One Agent.

Journal of experimental pharmacology·2021
Same author

Excess Mortality in Aspirin and Dipyrone (Metamizole) Co-Medicated in Patients With Cardiovascular Disease: A Nationwide Study.

Journal of the American Heart Association·2021
Same author

Can an Old Ally Defeat a New Enemy?

Circulation·2020

Variable responsiveness to acetylsalicylic acid (ASA) is common. While true pharmacological resistance exists, current lab tests for antiplatelet activity have limitations and results should not be over-interpreted without more trial data.

Area of Science:

  • Pharmacology
  • Cardiology
  • Clinical Medicine

Background:

  • Variable patient response to acetylsalicylic acid (ASA) is a recognized clinical issue.
  • Understanding the link between reduced antiplatelet activity and clinical outcomes is crucial.

Purpose of the Study:

  • To investigate the clinical reality of variable responsiveness to acetylsalicylic acid (ASA).
  • To explore the implications of "treatment failure" and reduced antiplatelet activity in patients.

Main Methods:

  • Quantification of platelet variability to ASA ex vivo using two major laboratory techniques: platelet function measurement and thromboxane formation measurement.
  • Acknowledging the limitations of current in vitro assays for defining ASA resistance.

Main Results:

Related Experiment Videos

  • Existing laboratory methods for assessing platelet variability to ASA have limitations and have not led to a universally accepted definition of ASA resistance.
  • True pharmacological resistance to ASA is identified in specific patient groups, but in vitro assay results require cautious interpretation.

Conclusions:

  • Further prospective trials are needed, particularly those measuring serum thromboxane formation, to better understand ASA responsiveness.
  • There is currently no evidence to support altering the standard daily maintenance dose of approximately 100 mg ASA for coronary protection.